

Cover Story
Lomustine, a.k.a. CCNU, is an old cancer drug.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Clinical Roundup


NCI Trials


NCI Trials for November 2019
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology - Imaging’s ride to the bottom in clinical trials—and why it matters now
- NIH says it’s moving away from animal-based models
- In the Headlines: Is oncology ready to move away from animal testing?
- The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic - ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population